Interaction with the mentioned proteins might destabilise AKT1, MDM2, and PRKN signalling pathways, which control cancer cells’ survival, proliferation, invasion, apoptosis, and angiogenesis, making the combined drug’s therapeutic effect promising. This evidence concerns the gene AKT1 and cancer.